|
Post by Clement on Jan 5, 2023 9:25:28 GMT -5
Best Momentum Stock to Buy for January 4th Zacks Equity Research Wed, January 4, 2023 at 10:00 AM EST
In this article: UTHR -0.18% CASY -0.62%
Here are two stocks with buy rank and strong momentum characteristics for investors to consider today, January 4th:
United Therapeutics UTHR: This company which is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally, has a Zacks Rank #1(Strong Buy)
|
|
|
Post by wyattdog on Jan 5, 2023 18:58:03 GMT -5
ALLISON GATLIN04:19 PM ET 01/05/2023 IBD Stock Of The Day United Therapeutics Is Braving Competition, And Eyeing Two Entries. ALLISON GATLIN04:19 PM ET 01/05/2023 United Therapeutics (UTHR) is the IBD Stock Of The Day as competition heats up in its bread-and-butter lung disease market. UTHR stock is eyeing two potential buy points.
The company is an expert in treating pulmonary arterial hypertension, a form of high blood pressure that affects the arteries in the lungs and right side of the heart. United sells several treatments for the condition, but is facing a looming rivalry with Merck. Merck is working on a first-in-class treatment for the same condition following its takeover of Acceleron Pharma.
UBS analyst Ashwani Verma isn't concerned about United's opportunity.
There's a "lot of pipeline activity in PAH, but limited direct impact to United's portfolio," Verma said in a December report. He initiated coverage of UTHR stock with a buy rating.
UTHR stock is finding support at its 21-day and 10-week moving lines, MarketSmith.com shows. It also formed a five-weeks-tight pattern with a buy point at 283.19. Shares could possibly find an earlier entry from a downward-sloping trend line around 278. UTHR Stock: Tyvaso Diversifying United Therapeutics sells a handful of treatments for pulmonary arterial hypertension, including two notable names, Tyvaso and Remodulin. Analysts expect sales of both rose during the fourth quarter. But Tyvaso sales are expected to soar more than 54% while Remodulin sales creep up 2.5%.
That's because Tyvaso sales are diversifying. United recently launched a new formulation of Tyvaso that uses a dry powder inhaler. The older form of Tyvaso utilized a different inhaled solution. United has also been able to gain approval for Tyvaso in patients with a rare lung disease called pulmonary hypertension associated with interstitial lung disease.
Verma, the UBS analyst, expects 57%-65% of patients with these diseases could use the new Tyvaso formulation. Meanwhile, another competitor is working on an alternative to Tyvaso. But Verma says Liquidia is unlikely to enter the market before March 2027.
"United's conversion to (dry powder inhaler) shields it from potential competition, while adding new patient growth for both (lung diseases)," he said. He also expects Tyvaso to be well shielded from Merck's experimental PAH treatment, sotatercept.
Verma assigned a 320 price target on UTHR stock.
Remodulin Could Stabilize Remodulin sales, on the other hand, have struggled with generic competition. But United recently relaunched its Remunity pump, a wearable device to deliver Remodulin. This will help it differentiate from shot formulations.
"We believe that Remunity starts, and total patients, can grow in the near/medium-term, supporting our above-consensus sales assumptions," Verma said.
Still, UTHR stock analysts aren't that bullish yet on Remodulin. According to FactSet, analysts expect sales to decline from 2022 to 2026. Tyvaso sales, on the other hand, are projected to grow from $608 million in 2021 to $1.87 billion by 2026.
Bullishly, shares of United Therapeutics have a strong Relative Strength Rating of 96 out of a best-possible 99. This means UTHR stock ranks in the top 4% of all stocks when it comes to 12-month performance, according to IBD Digital.
The stock has a Composite Rating of 95. The CR is a 1-99 measure of fundamental and technical measures.
|
|
|
Post by jkendra on Jan 5, 2023 19:02:16 GMT -5
|
|
|
Post by Clement on Jan 6, 2023 7:40:54 GMT -5
ALLISON GATLIN04:19 PM ET 01/05/2023 IBD Stock Of The Day United Therapeutics Is Braving Competition, And Eyeing Two Entries. ALLISON GATLIN04:19 PM ET 01/05/2023 United Therapeutics (UTHR) is the IBD Stock Of The Day ..... United Therapeutics sells a handful of treatments for pulmonary arterial hypertension, including two notable names, Tyvaso and Remodulin. Analysts expect sales of both rose during the fourth quarter. But Tyvaso sales are expected to soar more than 54% while Remodulin sales creep up 2.5%. That's because Tyvaso sales are diversifying. United recently launched a new formulation of Tyvaso that uses a dry powder inhaler. The older form of Tyvaso utilized a different inhaled solution. United has also been able to gain approval for Tyvaso in patients with a rare lung disease called pulmonary hypertension associated with interstitial lung disease. Verma, the UBS analyst, expects 57%-65% of patients with these diseases could use the new Tyvaso formulation. Meanwhile, another competitor is working on an alternative to Tyvaso. But Verma says Liquidia is unlikely to enter the market before March 2027. ..... "United Therapeutics sells a handful of treatments for pulmonary arterial hypertension, including two notable names, Tyvaso and Remodulin. Analysts expect sales of both rose during the fourth quarter. But Tyvaso sales are expected to soar more than 54% while Remodulin sales creep up 2.5%." 54% more than Q3 net Tyvaso revenue would give us 1.54 x $257.7 million = $396.8 million for Q4 If T-DPI is half that, we get $198.4 million for T-DPI in Q4.
|
|
|
Post by sla55 on Jan 9, 2023 9:47:15 GMT -5
|
|
|
Post by Clement on Jan 9, 2023 9:47:52 GMT -5
|
|
|
Post by kite on Jan 9, 2023 16:59:44 GMT -5
Is anyone listening right now?
|
|
|
Post by neil36 on Jan 25, 2023 12:47:19 GMT -5
|
|
|
Post by jkendra on Feb 7, 2023 8:56:44 GMT -5
finance.yahoo.com/news/tonix-pharmaceuticals-announces-research-agreement-120000936.htmlTonix Pharmaceuticals Announces Research Agreement with University of Maryland, Baltimore, to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Rejection in Heart Xenograft Transplantation in Animals Tonix Pharmaceuticals Holding Corp. Wed, February 1, 2023 at 7:00 AM EST CHATHAM, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has entered into a sponsored research agreement with the University of Maryland, Baltimore (UMB), for the prevention of rejection in heart xenograft transplantation in animals utilizing TNX-15001, an Fc-modified humanized monoclonal antibody directed against CD40-ligand. UMB’s preclinical studies will utilize genetically-modified porcine hearts supplied by Revivicor, Inc., a subsidiary of United Therapeutics Corporation. The principal investigator is Muhammad M. Mohiuddin, M.D., MBBS, Professor of Surgery, and Director, Cardiac Xenotransplantation Program, University of Maryland School of Medicine. “We are excited to collaborate with the University of Maryland and Dr. Mohiuddin on the development of TNX-1500 for the prevention of rejection in xenograft transplantation,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “TNX-1500 is a third generation anti-CD40L monoclonal antibody that has been designed by protein engineering to decrease FcγRII binding and to reduce the potential for thrombosis. Previous preclinical studies in non-human primates demonstrated that TNX-1500 showed activity in preventing allograft and xenograft organ rejection and was well tolerated. A positive result from this study would potentially help support an Investigational New Drug (IND) application and human clinical studies.” “Despite exciting advancements in the field of xenotransplantation, better therapeutics are needed to prevent xenograft organ rejection,” said Dr. Mohiuddin. “Several lines of research indicate that anti-CD40L is required for long term xenograft acceptance. We are excited to collaborate in support of developing an effective immunosuppression regimen for patients requiring xenograft transplantation.”
|
|
|
Post by Clement on Feb 15, 2023 9:05:55 GMT -5
|
|
|
Post by Clement on Feb 16, 2023 11:43:58 GMT -5
Last year, UTHR's FY2021 report was on Feb 24 at 9:00 am. (MNKD's FY2021 report was on Feb 24 at 5:00 pm.)
|
|
|
Post by peppy on Feb 22, 2023 7:50:11 GMT -5
|
|
|
Post by neil36 on Feb 22, 2023 7:54:59 GMT -5
UTHR Cost of Sales increased from $116.7 million to $146.7 million and is followed by this note:
"The increase in cost of sales for the year ended December 31, 2022, as compared to the same period in 2021, was primarily due to an increase in royalty expense and product costs for Tyvaso DPI following the commercial launch of the product in June 2022." (page 51)
|
|
|
Post by peppy on Feb 22, 2023 8:07:51 GMT -5
the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2022.
"We’re now focused on continued commercial uptake of Tyvaso and Tyvaso DPI in both PAH and PH-ILD to support our long-term goal of doubling our revenue to a $4 billion run rate by the end of 2025."
"We are tremendously proud of reaching our goal of doubling the number of patients on Tyvaso therapy since the Tyvaso PH-ILD approval in early 2021," said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. "We’re now focused on continued commercial uptake of Tyvaso and Tyvaso DPI in both PAH and PH-ILD to support our long-term goal of doubling our revenue to a $4 billion run rate by the end of 2025."
|
|
|
Post by anderson on Feb 22, 2023 8:17:36 GMT -5
4th quarter Cost of sales $55.9m 3rd quarter Cost of sales $37.1m MNKD Revenue $16.566m of that(collaborations and services $10.346m, Royalties — collaborations $6.220m) Lets hope UTHR's cost for others in the 4th quarter is similar and the increase is mostly MNKD collab, and royalties.
Probably a little too hopeful, but MNKD last quarters loss was $14.432m. Would love to see break even.
|
|